| 鲍 健,孙 祥,李红霞,刘 柳,汪 毅,耿春花.替吉奥联合阿帕替尼对晚期复发转移食管癌患者T细胞亚群和血清肿瘤标志物水平的影响[J].现代生物医学进展英文版,2021,(15):2958-2962. |
| 替吉奥联合阿帕替尼对晚期复发转移食管癌患者T细胞亚群和血清肿瘤标志物水平的影响 |
| Effect of Tegafur Combined with Apatinib on T Cell Subsets and Serum Tumor Markers in Patients with Advanced Recurrent and Metastatic Esophageal Cancer |
| Received:February 05, 2021 Revised:February 28, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.15.033 |
| 中文关键词: 替吉奥 阿帕替尼 晚期 复发转移食管癌 疗效 T细胞亚群 肿瘤标志物 |
| 英文关键词: Tegafur Apatinib Advanced Recurrent and metastatic esophageal cancer Efficacy T cell subsets Tumor markers |
| 基金项目:安徽省自然科学基金项目（1508085MH195） |
|
| Hits: 630 |
| Download times: 376 |
| 中文摘要: |
| 摘要 目的：观察晚期复发转移食管癌经阿帕替尼联合替吉奥治疗后的疗效及对患者T细胞亚群和血清肿瘤标志物水平的影响。方法：病例搜集时间为2015年3月至2018年3月，病例搜集范围为我院接收的晚期复发转移食管癌患者70例。采用信封抽签法将患者分为对照组和实验组，各为35例。对照组给予替吉奥治疗，实验组在对照组的基础上联合阿帕替尼治疗，两组均连续化疗2个周期。对比两组化疗2个周期后的客观缓解率、疾病控制率；对比两组化疗前、化疗2个周期后的T细胞亚群和血清肿瘤标志物水平；对比两组中位总生存期（mOS）、中位无进展生存期（mPFS）及生命质量评分，记录两组化疗期间毒副反应发生情况。结果：实验组的客观缓解率45.71%、疾病控制率68.57%高于对照组的22.86%、42.86%（P<0.05）。两组化疗2个周期后CD3+、CD4+、CD4+/ CD8+均较化疗前降低，但实验组高于对照组（P<0.05）；CD8+较化疗前升高，但实验组低于对照组（P<0.05）。两组化疗2个周期后肿瘤特异性生长因子（TSGF）、癌胚抗原（CEA）、糖类抗原199（CA199）较化疗前降低，且实验组低于对照组（P<0.05）。实验组的mOS、mPFS长于对照组（P<0.05），两组化疗结束后3个月QLQ-OES24评分均升高，且实验组高于对照组（P<0.05）。两组不良反应发生率对比，差异无统计学意义（P>0.05）。结论：晚期复发转移食管癌经阿帕替尼联合替吉奥治疗后，病情得到有效控制，血清肿瘤标志物水平降低更为显著，同时还可减轻免疫抑制，延长mOS、mPFS，且不增加毒副反应，近期疗效可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the efficacy of tegafur combined with apatinib in the treatment of advanced recurrent and metastatic esophageal cancer and its effect on T cell subsets and serum tumor marker levels. Methods: The case collection time was from March 2015 to March 2018, and the case collection scope was 70 patients with advanced recurrent and metastatic esophageal cancer in our hospital. The patients were divided into control group and experimental group by envelope lottery, with 35 cases in each group. The control group was treated with tegafur, and the experimental group was treated with apatinib on the basis of the control group. Both groups received chemotherapy for 2 cycles. Objective remission rate and disease control rate at 2 cycles after chemotherapy were compared between the two groups. T cell subsets and serum tumor markers levels before and 2 cycles after chemotherapy were compared between the two groups. Median overall survival (mOS), median progression free survival (mPFS) and quality of life scores were compared between the two groups. The toxicological and side effects during chemotherapy were recorded. Results: The objective remission rate and disease control rate of the experimental group were 45.71% and 68.57% respectively, which were higher than 22.86% and 42.86% of the control group (P<0.05). 2 cycles after chemotherapy, CD3+, CD4+, CD4+/CD8+ of two groups were lower than those before chemotherapy, but the experimental group was higher than the control group(P<0.05). CD8+ was higher than that before chemotherapy, but the experimental group was lower than the control group (P<0.05). 2 cycles after chemotherapy, the levels of tumor specific growth factor (TSGF), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) of two groups were lower than those before chemotherapy, and the experimental group was lower than the control group (P<0.05). The mOS and mPFS of the experimental group were longer than those of the control group(P<0.05). The QLQ-OES24 score of the two groups at 3 months after chemotherapy increased, and the experimental group was higher than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: After treatment of advanced recurrent and metastatic esophageal cancer with tegafur combined with apatinib, the condition is effectively controlled, the serum tumor markers levels are decreased more significantly, the immunosuppression is alleviated, the mOS and mPFS are prolonged, and the side effects are not increased. The short-term curative effects is reliable. |
|
View Full Text
View/Add Comment Download reader |
| Close |
